IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

RUMI, MARIAGRAZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 10.982
NA - Nord America 5.688
AS - Asia 3.355
SA - Sud America 141
AF - Africa 50
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 10
Totale 20.258
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.495
GB - Regno Unito 5.163
DE - Germania 1.858
CN - Cina 1.479
IT - Italia 1.001
SE - Svezia 896
SG - Singapore 622
RU - Federazione Russa 505
UA - Ucraina 385
IN - India 331
TR - Turchia 320
IE - Irlanda 290
KR - Corea 230
FR - Francia 217
EU - Europa 187
CA - Canada 181
FI - Finlandia 164
NL - Olanda 139
DK - Danimarca 131
CO - Colombia 94
HK - Hong Kong 93
VN - Vietnam 82
ID - Indonesia 63
GR - Grecia 56
BE - Belgio 41
PL - Polonia 41
AU - Australia 27
BR - Brasile 27
IR - Iran 25
CH - Svizzera 23
RO - Romania 23
EG - Egitto 21
JP - Giappone 20
PK - Pakistan 18
UZ - Uzbekistan 18
TW - Taiwan 15
CL - Cile 13
ES - Italia 11
IL - Israele 9
UG - Uganda 9
TH - Thailandia 8
CZ - Repubblica Ceca 7
MX - Messico 7
PT - Portogallo 7
AT - Austria 6
KE - Kenya 6
MY - Malesia 5
NZ - Nuova Zelanda 5
CR - Costa Rica 4
AR - Argentina 3
ET - Etiopia 3
IQ - Iraq 3
JO - Giordania 3
NO - Norvegia 3
SC - Seychelles 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BY - Bielorussia 2
CY - Cipro 2
EE - Estonia 2
IS - Islanda 2
MA - Marocco 2
MD - Moldavia 2
OM - Oman 2
PE - Perù 2
SK - Slovacchia (Repubblica Slovacca) 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BG - Bulgaria 1
BJ - Benin 1
BN - Brunei Darussalam 1
EC - Ecuador 1
JE - Jersey 1
KH - Cambogia 1
KW - Kuwait 1
LT - Lituania 1
MU - Mauritius 1
NG - Nigeria 1
PA - Panama 1
PH - Filippine 1
RS - Serbia 1
SN - Senegal 1
VE - Venezuela 1
Totale 20.437
Salva come PNG Salva come JPEG
Città #
Southend 4.918
Chandler 721
Frankfurt am Main 466
Seattle 450
Singapore 449
Milan 350
Beijing 340
Princeton 330
Jacksonville 301
Dublin 287
Wilmington 284
Ashburn 249
Ann Arbor 229
Fairfield 217
Dearborn 196
Nanjing 169
Woodbridge 167
Hanover 161
Mountain View 159
Redmond 158
Toronto 150
Houston 143
Serra 128
Somerville 118
Andover 115
Des Moines 112
Boardman 109
Sakarya 105
Bengaluru 103
Santa Clara 99
Bogotá 94
Jinan 91
Cambridge 88
Berlin 82
Hong Kong 72
Shanghai 66
Shenyang 66
New York 52
Nanchang 51
Phoenix 51
Redwood City 50
Hebei 42
Saint Petersburg 42
Jiaxing 41
Dong Ket 40
Helsinki 40
Brussels 38
Athens 37
Warsaw 35
Eitensheim 34
Hangzhou 34
Guangzhou 33
Grafing 31
Kunming 28
Tianjin 28
Istanbul 27
Jakarta 26
Changsha 25
Fremont 25
Margão 25
Ottawa 25
Segrate 25
Hamburg 24
San Diego 24
Zhengzhou 24
Fuzhou 23
Auburn Hills 22
Bitonto 22
Turin 22
Mumbai 21
Munich 20
Pisa 20
Los Angeles 19
Taiyuan 19
Haikou 18
Piscataway 18
Bühl 17
Kent 16
Central District 15
London 15
Gorla Maggiore 14
Hefei 13
Quanzhou 12
Roxbury 12
Falls Church 11
Taizhou 11
Verona 11
Lanzhou 10
Ningbo 10
Norwalk 10
Silver Spring 10
Tokyo 10
Bologna 9
Islamabad 9
Kampala 9
Montecassiano 9
Tehran 9
Wuhan 9
Chengdu 8
Pune 8
Totale 13.790
Salva come PNG Salva come JPEG
Nome #
Forecasting Hepatitis C liver disease burden on real life data: Does the hidden iceberg matter to reach the elimination goals? 598
Management of HCV-Related Liver Disease in Hemophilia and Thalassemia 351
Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients 304
Prevalence of psychiatric disorders during PEG – Interferon and Ribavirin therapy in patients with chronic hepatitis HCV-correlated 269
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent 264
Anti-LAV/HTLV-III antibodies in groups of individuals at high risk for infection in Italy 244
Anti-LAV/HTLV-III antibodies in high and low risk groups 219
The international autoimmune hepatitis group scoring system in patients with chronic hepatitis C and serum autoantibodies undergoing interferon/ribavirin therapy : a prospective validation study 206
Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance 198
Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis 197
Onset of inflammatory bowel disease during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases 194
Hepatitis C virus deletion mutants are found in individuals chronically infected with genotype 1 hepatitis c virus in association with age, high viral load and liver inflammatory activity 192
Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon 183
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 183
High rates of 30-day mortality in patients with cirrhosis and COVID-19 182
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia 180
US features of liver surface nodularity as a predictor of severe fibrosis in chronic hepatitis C 177
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegykated interferon-α2A in chronic hepatitis C : an in vitro and in vivo study 177
A 28-Year Study of the Course of Hepatitis Delta Infection : A Risk Factor for Cirrhosis and Hepatocellular Carcinoma 177
Anemia during pegylated interferon-ribavirin therapy results from both increase suppression of erythroid differentiation and hemolysis 176
Transmission of hepatitis G virus in patients with angioedema treated with steam-heated plasma concentrates of C1 inhibitor 175
Genotype dependent pattern of peginterferon alfa-2b/ribavirin treatment failure in hepatiti sC virus infected patients with cirrhosis : a single center study of 471 naive patients 174
Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving telaprevir 173
Hepatitis C virus genotypes and patterns of peginterferon alfa-2b/ribavirin treatment failure in patients with cirrhosis : a single center study of 471 naïve patients 172
Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients 171
The natural history of portal hypertension in patients with HCV related compensated cirrhosis undergoing interferon ribavirin therapy 170
A sequential predictive algorithm combining APRI and transient elastography (TE) for diagnosing liver fibrosis in chronic hepatitis C 169
The candidate HCV E1E2MF59 vaccine is safe in chronic hepatitis C patients and accellerates the second phase viral decline upon primary response to peg-interferon-2A/ribavirin therapy 169
The candidate HCV E1E2MF59 vaccine enhances 2nd phase viral decline in responders to PEG-IFN/ribavirin 167
Serum hepatitis B virus DNA detects cryptic hepatitis B virus infections in multitransfused hemophilic patients 165
In vivo and in vitro effect of ribavirin and interferon on erythropoiesis in patients with hepatitis C 164
Genotype dependent pattern of Peginterferon alfa-2B/Ribavirin treatment failure in hepatitis C virus infected patients with cirrhosis : a single centre study of 471 naïve patients 163
Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma 163
The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy 162
Increased survival of patients with HCV-related cirrhosis with a long-term response to interferon therapy 160
The influence of liver fibrosis on the outcome of pegylated interferon and ribavirin anti-hac therapy : a sub-analysis of the mist study 157
NPLA3 I148M polymorphism, steatosis, liver damage, and treatment response in chronic hepatitis C 157
Recovery after L-DOPA treatment in peg-interferon and ribavirin induced parkinsonism 156
The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies 156
A morphometric and immunohistochemical study to assess the benefit of an svr in hcv cirrhotic patients 156
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 156
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegylated interferon-alpha 2a in chronic hepatitis C : an in vitro and in vivo study 153
Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C 153
Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C 153
Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease 152
Trattamento della cirrosi epatica HCV-correlata 151
PNPLA3 I148M polymorphism, steatosis, liver damage, and treatment response in chronic hepatitis C 150
Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients : a single-centre study 146
Standard and pegylated interferon alfa-2b plus ribavirin as initial treatment for HCV genotype 2 chronic hepatitis : analysis of a large single center cohort 145
The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males : an international, multicenter study 145
Optimizing treatment with pegylated interferon-ribavirin of genotype 3 chronic hepatitis C : more questions than answers 143
Low risk of hepatitis B reactivation in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 143
Primary prophylaxis of variceal bleeding in cirrhotic patients : a cohort study 143
The diagnostic accuracy of fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with an SVR 143
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 142
A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C 141
The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype 140
Low risk of hepatitis B reactivatioin in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 140
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4 140
Interferoni pegilati nel trattamento dei pazienti con epatite cronica HCV : esperienze a confronti 139
Low rates of sustained virological response to interferon and ribavirin therapy in genotype 3 infected patients with compensated cirrhosis 139
Serum levels of hepatitis C virus core antigen as a markers of infection and response to therapy 138
Epatiti virali acute 138
Suboptimal response to hepatitis B vaccine in drug users 138
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 138
In vitro effect of ribavirin and pegylated interferon on erythropoiesis 137
Twelve-week post-treatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy 137
Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c : a retrospective cohort study of 206 untreated patients 136
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection 136
Accelerated schedule of hepatitis B vaccination in patients with hemophilia 135
Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1b chronic hepatitis C : A randomized controlled trial 134
Evaluation of liver disease in a cohort of patients affected by thalassemia intermedia 134
A sequential predictive algorithm combining APRI and transient elastography (TE) for diagnosing liver fibrosis in chronic hepatitis C 134
Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy 134
Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3α hepatitis C virus infection 133
Increased risk of hepatocellular carcinoma in HCV (+) non responder cirrhotics with high liver cell proliferation 133
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis 133
Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients 132
The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis 131
The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease : A cohort study 130
Imatinib in CML patients HBCAB and/or HCVAB positive : report of two cases 130
Randomized Study of Peginterferon-alpha2a Plus Ribavirin vs Peginterferon-alpha2b Plus Ribavirin in Chronic Hepatitis C 130
Ribavirin impairs salivary gland function in hepatitis C patients during combination treatment with pegylated interferon alfa-2a 130
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 130
In vivo and in vitro effect of ribavirin and pegylated-interferon on erythropoiesis in patients with hepatitis C 129
Liver cell proliferation and liver cancer risk in patients with hepatitis C virus-related cirrhosis under antiviral treatment 128
In vivo and in vitro effect of ribavirin and interferon on erythropoiesis in patients with hepatitis C 127
Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients 126
A sequential predictive algorithm combining APRI and transient elastography for diagnosing liver fibrosis in chronic hepatitis C 126
Lack of alanine aminotransferase normalization in patients with an anti-hcv virological response during pegylated interferon and ribavirin therapy : a sub-analysis of the mist study 124
Antiviral Therapy for HCV-Associated Cryoglobulinemic Glomerulonephritis : Case Report and Review of the Literature 123
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pone.0172159) 123
High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C 122
Le epatiti virali acute 121
The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin 121
Natural history and clinical impact of cryoglobulins in chronic hepatitis C : 10-year prospective study of 343 patients 121
Independent predictors of discordance between transient elastography (TE) and liver biopsy 121
Low body mass index (BMI) predicts discordance between transient elastography (TE) and liver biopsy (LB) assessment of liver fibrosis 120
Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics? 120
Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C 120
Totale 16.080
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.437
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.437
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.953 0 0 0 0 174 307 273 193 491 276 144 95
2020/20213.041 225 244 211 117 261 159 210 317 283 172 592 250
2021/20222.280 230 115 69 127 139 161 225 192 238 277 157 350
2022/20232.426 323 269 204 281 260 482 46 125 270 23 106 37
2023/20241.790 45 115 77 142 529 118 129 107 59 93 153 223
2024/20251.202 155 414 63 412 158 0 0 0 0 0 0 0
Totale 21.483